Genmab — December 2021
-
Aktier/tendens: Grøn dag i sigte med Genmab og Ørsted i søgelyset https://www.proinvestor.com/investornyt/743003/aktier-tendens-gron-dag-i-sigte-med-genmab-og-orsted-i-sogelyset
-
Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives https://touchoncology.com/gynaecological-oncology/journal-articles/tisotumab-vedotin-in-cervical-cancer-current-status-and-future-perspectives/
-
Det for useriøst at have salgsanbefaling på dette kursniveau baseret nogle luftige vurderinger af pipelinens fremtidige salgspotentiale på den l
ange bane, når man samtidigt anerkender blockbusterpontialet på den mellemlange. -
på nogle
-
Jeg læser det ikke som de siger 2 BB. Men 2 andre stoffer med potentiale som dara. Altså at det er DET de mener den nuværende mcap bygger på
-
@Vitus absolutely. However, never overestimate the market or underestimate your own knowledge
But everyone is allowed to have an opinion; actually the opposing opinions are often the most interesting, as we can possibly learn something from them. Let’s face it; we all suffer from investor bias sometimes. The only problem here is that i don’t have the berenberg report, so i can’t judge it. -
Det må da være en abnorm lav værdi (!) Berenberg sætter på Dara, samtidigt med at de bekræfter et peak på 12 bUSD forudsat, at dagsværdien ca. 2500, indeholder værdien af 2 produkter med "Dara-værdi". Jeg er mere forvirret end oplyst efter den analyse
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind